Enzo Biochem to Present at Needham Healthcare Conference

Download as PDF

NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Barry Weiner, President, and David Goldberg, Vice President, Corporate Development, and Interim President Enzo Clinical Labs, will be presenting at the 11th Annual Needham Healthcare Conference on Tuesday Apr 3, 2012 at 8:00 AM at The New York Palace Hotel in New York, N.Y. Interested parties may listen to the presentation over the Internet at: http://wsw.com/webcast/needham51/enz/

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and rapidly deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

Enzo Biochem, Inc.
Steven Anreder, 212-532-3232
or
CEOcast, Inc.
Michael Wachs, 212-732-4300

Source: Enzo Biochem, Inc.

Released March 27, 2012